Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Paul Weiden, M.D.
KFSYSCC consultant
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Cheng Kung University Hospital (nckuh)
Tainan, North Dist., Taiwan
- Koo Foundation Sun Yat-Sen Cancer Center (kfsyscc)
Taipei, Pei-Tou Dist., Taiwan
- National Taiwan University Hospital (ntuh)
Taipei, Zhongzheng Dist., Taiwan
- Kfsyscc
Taipei, Taiwan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Jan 2021
- Primary completion
- 9 Apr 2026
- Completion
- 9 Apr 2026
- Last update posted
- 25 Aug 2026
- Registered enrollment
- 12
- Registry id
- NCT04601428
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.